Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
340 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Neuroblastoma - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Neuroblastoma - Pipeline Review, H2 2015', provides an overview of the Neuroblastoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Neuroblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuroblastoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Neuroblastoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Neuroblastoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Neuroblastoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Neuroblastoma Overview 10 Therapeutics Development 11 Pipeline Products for Neuroblastoma - Overview 11 Pipeline Products for Neuroblastoma - Comparative Analysis 12 Neuroblastoma - Therapeutics under Development by Companies 13 Neuroblastoma - Therapeutics under Investigation by Universities/Institutes 18 Neuroblastoma - Pipeline Products Glance 21 Late Stage Products 21 Clinical Stage Products 22 Early Stage Products 23 Neuroblastoma - Products under Development by Companies 24 Neuroblastoma - Products under Investigation by Universities/Institutes 29 Neuroblastoma - Companies Involved in Therapeutics Development 31 Ability Pharma, SL 31 Acetylon Pharmaceuticals, Inc. 32 Advanced Accelerator Applications SA 33 Ampio Pharmaceuticals, Inc. 34 APEIRON Biologics AG 35 AstraZeneca Plc 36 ATLAB Pharma SAS 37 Bellicum Pharmaceuticals, Inc. 38 Bexion Pharmaceuticals, LLC. 39 BioLineRx, Ltd. 40 Bionucleon Srl 41 Biotec Pharmacon ASA 42 Cebiotex, S.L. 43 Celgene Corporation 44 Chugai Pharmaceutical Co., Ltd. 45 Cleveland BioLabs, Inc. 46 CureFAKtor Pharmaceuticals, LLC 47 Cyclacel Pharmaceuticals, Inc. 48 DEKK-TEC, Inc. 49 Errant Gene Therapeutics, LLC 50 F. Hoffmann-La Roche Ltd. 51 GlaxoSmithKline Plc 52 Ignyta, Inc. 53 Juno Therapeutics Inc. 54 Lindis Biotech GmbH 55 MabVax Therapeutics Holdings, Inc. 56 MEI Pharma, Inc. 57 Merck & Co., Inc. 58 Merrimack Pharmaceuticals, Inc. 59 Novartis AG 60 Novogen Limited 61 Pharmacyclics, Inc. 62 Pono Pharma 63 Progenics Pharmaceuticals, Inc. 64 Recombio S.L 65 Ribomic Inc. 66 Sareum Holdings Plc 67 Shionogi & Co., Ltd. 68 Sutro Biopharma, Inc. 69 Teva Pharmaceutical Industries Limited 70 Threshold Pharmaceuticals, Inc. 71 Neuroblastoma - Therapeutics Assessment 72 Assessment by Monotherapy Products 72 Assessment by Combination Products 73 Assessment by Target 74 Assessment by Mechanism of Action 78 Assessment by Route of Administration 82 Assessment by Molecule Type 84 Drug Profiles 86 1-B7 - Drug Profile 86 31-F9 - Drug Profile 87 abexinostat hydrochloride - Drug Profile 88 ABTL-0812 - Drug Profile 91 ACY-957 - Drug Profile 93 AMB-8LK - Drug Profile 94 AMXT-1501 + eflornithine hydrochloride - Drug Profile 95 Antisense RNAi Oligonucleotide for Oncology - Drug Profile 97 APN-301 - Drug Profile 98 APN-311 - Drug Profile 99 ATL-301 - Drug Profile 101 ATL-302 - Drug Profile 102 ATM-3507 - Drug Profile 103 AZ-64 - Drug Profile 104 BACPT-DP - Drug Profile 105 bevacizumab - Drug Profile 107 BL-8040 - Drug Profile 113 BN-210 - Drug Profile 115 BPX-701 - Drug Profile 116 BXQ-350 - Drug Profile 117 CCT-244747 - Drug Profile 119 CCT-245737 - Drug Profile 121 CCT-68127 - Drug Profile 123 CEB-01 - Drug Profile 124 Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile 125 Cellular Immunotherapy for Neuroblastoma - Drug Profile 127 Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile 128 Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile 129 Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile 130 celyvir - Drug Profile 131 CEP-28122 - Drug Profile 133 CFAKY-15 - Drug Profile 134 CG-1521 - Drug Profile 135 CSG-007 - Drug Profile 136 CVE-199 - Drug Profile 137 CYC-065 - Drug Profile 138 Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 139 Edotreotide Labeled Yttrium 90 - Drug Profile 140 eflornithine hydrochloride - Drug Profile 142 eh8B6 - Drug Profile 144 entrectinib - Drug Profile 145 evofosfamide - Drug Profile 147 firtecan pegol - Drug Profile 155 FSEC - Drug Profile 157 GSK-525762 - Drug Profile 158 iobenguane sulfate I 131 - Drug Profile 159 irinotecan hydrochloride - Drug Profile 161 JCAR-023 - Drug Profile 164 Lutathera - Drug Profile 165 M-606 - Drug Profile 168 M-7085 - Drug Profile 169 Monoclonal Antibody Conjugate to Target B7-H3 for Cancer - Drug Profile 170 Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 171 Monoclonal Antibody to Target CD3 for Neuroblastoma - Drug Profile 172 Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma - Drug Profile 173 Monoclonal Antibody to Target GD2 and CD3 for Neuroblastoma and Melanoma - Drug Profile 175 Monoclonal Antibody to Target GD2 for Neuroblastoma - Drug Profile 176 NCE-001 - Drug Profile 177 Oncolytic Virus for Oncology - Drug Profile 178 P-937 - Drug Profile 179 paclitaxel albumin bound - Drug Profile 180 pazopanib hydrochloride - Drug Profile 184 pembrolizumab - Drug Profile 190 Peptide to Inhibit HDAC for Neuroblastoma - Drug Profile 199 pracinostat - Drug Profile 200 racotumomab - Drug Profile 202 RBM-001 - Drug Profile 204 Recombinant Protein to Inhibit HDAC for Neuroblastoma - Drug Profile 206 ribociclib - Drug Profile 207 RKS-262 - Drug Profile 210 RNAi Oligonucleotides for Neuroblastoma - Drug Profile 211 RSF-701 - Drug Profile 212 S-588410 - Drug Profile 213 SAR-020106 - Drug Profile 214 SAR-4 - Drug Profile 216 SF-1126 - Drug Profile 217 Small Molecules for Neuroblastoma - Drug Profile 219 Small Molecules for Neuroblastoma - Drug Profile 220 Small Molecules to Antagonize ALK for Oncology - Drug Profile 221 Soluble Beta Glucan - Drug Profile 222 SRX-2523 - Drug Profile 225 Syrbactins - Drug Profile 227 TL-118 - Drug Profile 228 TPI-287 - Drug Profile 230 TR-100 - Drug Profile 232 TRBS-07 - Drug Profile 233 Trilexium - Drug Profile 234 Vaccine 1 for Oncology - Drug Profile 235 Vaccine for Neuroblastoma - Drug Profile 236 Vaccine for Neuroblastoma - Drug Profile 238 Vaccine for Neuroblastoma - Drug Profile 239 X-396 - Drug Profile 240 Neuroblastoma - Recent Pipeline Updates 241 Neuroblastoma - Dormant Projects 319 Neuroblastoma - Discontinued Products 322 Neuroblastoma - Product Development Milestones 323 Featured News & Press Releases 323 Appendix 332 Methodology 332 Coverage 332 Secondary Research 332 Primary Research 332 Expert Panel Validation 332 Contact Us 332 Disclaimer 333
List of Tables
Number of Products under Development for Neuroblastoma, H2 2015 18 Number of Products under Development for Neuroblastoma - Comparative Analysis, H2 2015 19 Number of Products under Development by Companies, H2 2015 21 Number of Products under Development by Companies, H2 2015 (Contd..1) 22 Number of Products under Development by Companies, H2 2015 (Contd..2) 23 Number of Products under Development by Companies, H2 2015 (Contd..3) 24 Number of Products under Investigation by Universities/Institutes, H2 2015 26 Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 27 Comparative Analysis by Late Stage Development, H2 2015 28 Comparative Analysis by Clinical Stage Development, H2 2015 29 Comparative Analysis by Early Stage Development, H2 2015 30 Products under Development by Companies, H2 2015 31 Products under Development by Companies, H2 2015 (Contd..1) 32 Products under Development by Companies, H2 2015 (Contd..2) 33 Products under Development by Companies, H2 2015 (Contd..3) 34 Products under Development by Companies, H2 2015 (Contd..4) 35 Products under Investigation by Universities/Institutes, H2 2015 36 Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 37 Neuroblastoma - Pipeline by Ability Pharma, SL, H2 2015 38 Neuroblastoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015 39 Neuroblastoma - Pipeline by Advanced Accelerator Applications SA, H2 2015 40 Neuroblastoma - Pipeline by Ampio Pharmaceuticals, Inc., H2 2015 41 Neuroblastoma - Pipeline by APEIRON Biologics AG, H2 2015 42 Neuroblastoma - Pipeline by AstraZeneca Plc, H2 2015 43 Neuroblastoma - Pipeline by ATLAB Pharma SAS, H2 2015 44 Neuroblastoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015 45 Neuroblastoma - Pipeline by Bexion Pharmaceuticals, LLC., H2 2015 46 Neuroblastoma - Pipeline by BioLineRx, Ltd., H2 2015 47 Neuroblastoma - Pipeline by Bionucleon Srl, H2 2015 48 Neuroblastoma - Pipeline by Biotec Pharmacon ASA, H2 2015 49 Neuroblastoma - Pipeline by Cebiotex, S.L., H2 2015 50 Neuroblastoma - Pipeline by Celgene Corporation, H2 2015 51 Neuroblastoma - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2015 52 Neuroblastoma - Pipeline by Cleveland BioLabs, Inc., H2 2015 53 Neuroblastoma - Pipeline by CureFAKtor Pharmaceuticals, LLC, H2 2015 54 Neuroblastoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015 55 Neuroblastoma - Pipeline by DEKK-TEC, Inc., H2 2015 56 Neuroblastoma - Pipeline by Errant Gene Therapeutics, LLC, H2 2015 57 Neuroblastoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 58 Neuroblastoma - Pipeline by GlaxoSmithKline Plc, H2 2015 59 Neuroblastoma - Pipeline by Ignyta, Inc., H2 2015 60 Neuroblastoma - Pipeline by Juno Therapeutics Inc., H2 2015 61 Neuroblastoma - Pipeline by Lindis Biotech GmbH, H2 2015 62 Neuroblastoma - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2015 63 Neuroblastoma - Pipeline by MEI Pharma, Inc., H2 2015 64 Neuroblastoma - Pipeline by Merck & Co., Inc., H2 2015 65 Neuroblastoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015 66 Neuroblastoma - Pipeline by Novartis AG, H2 2015 67 Neuroblastoma - Pipeline by Novogen Limited, H2 2015 68 Neuroblastoma - Pipeline by Pharmacyclics, Inc., H2 2015 69 Neuroblastoma - Pipeline by Pono Pharma, H2 2015 70 Neuroblastoma - Pipeline by Progenics Pharmaceuticals, Inc., H2 2015 71 Neuroblastoma - Pipeline by Recombio S.L, H2 2015 72 Neuroblastoma - Pipeline by Ribomic Inc., H2 2015 73 Neuroblastoma - Pipeline by Sareum Holdings Plc, H2 2015 74 Neuroblastoma - Pipeline by Shionogi & Co., Ltd., H2 2015 75 Neuroblastoma - Pipeline by Sutro Biopharma, Inc., H2 2015 76 Neuroblastoma - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015 77 Neuroblastoma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015 78 Assessment by Monotherapy Products, H2 2015 79 Assessment by Combination Products, H2 2015 80 Number of Products by Stage and Target, H2 2015 82 Number of Products by Stage and Mechanism of Action, H2 2015 86 Number of Products by Stage and Route of Administration, H2 2015 90 Number of Products by Stage and Molecule Type, H2 2015 92 Neuroblastoma Therapeutics - Recent Pipeline Updates, H2 2015 248 Neuroblastoma - Dormant Projects, H2 2015 326 Neuroblastoma - Dormant Projects (Contd..1), H2 2015 327 Neuroblastoma - Dormant Projects (Contd..2), H2 2015 328 Neuroblastoma - Discontinued Products, H2 2015 329
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
